DE | Accessible presentation
Translations are powered by AI

The most important investments of the fourth quarter of 2022

Lilium, Holidu, Catalym – numerous startups from Munich and the surrounding area have successfully raised funding in the past three months. This photo gallery provides an overview of the largest investments of the fourth quarter.

December 21, 2022 3 min reading time

Catalym
Catalym secures 50 million euros: After a Series B round of 50 million euros two years ago, Catalym can once again 50 million euros In addition to Bayern Kapital, Forbion, Novartis Venture Fund, Vesalius Biocapital III, BioGeneration Ventures, and Coparion are participating in the Series C financing round from existing investors. Brandon Capital and Jeito Capital are joining as lead investors. With the new funding, the IZB company plans to initiate the second phase of the development program for its drug candidate Visugromab. Visugromab is designed to neutralize a specific protein that tumors use to protect themselves from the body's immune system. This should make tumors accessible to the immune system again, thus strengthening the immune system.
read more ↓